Clinical Trial Detail

NCT ID NCT03272464
Title Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

melanoma

Advanced Solid Tumor

Therapies

Dabrafenib + Itacitinib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST